AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22790524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 107
Study 20430262 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (up to 54 mug) 4 times daily
Number of subjects: 235
Study 20430262 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 235
Study 18955906 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestalt grouping cues (proximity or similarity)
Number of subjects: 0
Study 18955906 — intervention group
Group type: COMPARATOR
Intervention: Neurological patients with damage to the inferior parietal regions
Number of subjects: 0
Study 16201941 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated polyglactin 910 suture with triclosan
Number of subjects: 0
Study 16201941 — intervention group
Group type: COMPARATOR
Intervention: Coated polyglactin 910 suture
Number of subjects: 0
Study 16201941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sutures
Number of subjects: 0
Study 12417963 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 31
Study 12417963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10536564 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaGraph neuromuscular monitor
Number of subjects: 20
Study 10536564 — intervention group
Group type: COMPARATOR
Intervention: Relaxometer 2 mechanomyograph
Number of subjects: 20
Study 10536564 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both monitors
Number of subjects: 20
Study 8652332 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 60 mg kg‐1 at recovery from vecuronium block to a TOF ratio of 0.7
Number of subjects: 20
Study 8652332 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 60 mg kg‐1 1 h after recovery to a TOF ratio of 0.7
Number of subjects: 20
Study 1853696 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide-oxygen (Group I)
Number of subjects: 50
Study 1853696 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen (Group II)
Number of subjects: 50
Study 6354282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (200‐300 mg over 48‐72 h)
Number of subjects: 397
Study 6354282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 397
Study 6354282 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 397
Study 30515964 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-backward method
Number of subjects: 60
Study 30515964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-panel method
Number of subjects: 60
Study 28841725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus loudness rating
Number of subjects: 91
Study 28841725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus loudness matching test
Number of subjects: 91
Study 25956017 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (2 interactive classroom sessions about sugar)
Number of subjects: 268
Study 25956017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 268
Study 25956017 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 268
Study 23603409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (HT)
Number of subjects: 0
Study 23603409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23603409 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogenic treatment
Number of subjects: 0
Study 21502892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with weight loss
Number of subjects: 22
Study 21502892 — intervention group
Group type: COMPARATOR
Intervention: Exercise training without weight loss
Number of subjects: 22
Study 21502892 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercising)
Number of subjects: 22
Study 18180279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml triamcinolonacetonide (TCA)
Number of subjects: 50
Study 18180279 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 50
Study 16480828 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral epidural stimulation electrodes
Number of subjects: 17
Study 16480828 — intervention group
Group type: COMPARATOR
Intervention: Double-blind testing
Number of subjects: 17
Study 15483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin monotherapy (3 postoperative courses)
Number of subjects: 35
Study 15483019 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 35
Study 15483019 — intervention group
Group type: COMPARATOR
Intervention: Remaining group (not specified treatment)
Number of subjects: 35
Study 11154750 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 271
Study 11154750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 271
Study 11154750 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 271
Study 11154750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 271
Study 9356089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 214
Study 9356089 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 214
Study 8502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent non-target tones (P=0.70)
Number of subjects: 16
Study 8502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-evoked N2 and P3b components
Number of subjects: 16
Study 8502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel stimuli
Number of subjects: 16
Study 8502373 — intervention group
Group type: EXPERIMENTAL
Intervention: P3a component
Number of subjects: 16
Study 2949481 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 2 mg + EE 50 micrograms (Diane)
Number of subjects: 133
Study 2949481 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 2 mg + EE 35 micrograms (Diane mite)
Number of subjects: 133
Study 2949481 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 150 micrograms + EE 30 micrograms (Neovletta)
Number of subjects: 133
Study 30852167 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 119
Study 30852167 — intervention group
Group type: COMPARATOR
Intervention: Higher star-rated NHs
Number of subjects: 119
Study 30852167 — intervention group
Group type: EXPERIMENTAL
Intervention: Champions' participation in check-in calls
Number of subjects: 119
Study 28783413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Number of subjects: 1039
Study 28783413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 µg
Number of subjects: 1039
Study 28783413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 1039
Study 28783413 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 1039
Study 28783413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study 28821523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic school-based universal resilience intervention (2012-2014)
Number of subjects: 2105
Study 26302900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouldering intervention (once a week for three hours over eight weeks)
Number of subjects: 47
Study 26302900 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (treatment as usual for eight weeks)
Number of subjects: 47
Study 23473357 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS
Number of subjects: 392
Study 21209131 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 90 min team-skills training sessions focused on findings from a standardised safety-culture survey
Number of subjects: 0
Study 21209131 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention period)
Number of subjects: 0
Study 18081357 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg IV and 20 mg orally)
Number of subjects: 21
Study 18081357 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg IV and 80 mg orally)
Number of subjects: 21
Study 16958947 — intervention group
Group type: EXPERIMENTAL
Intervention: milameline
Number of subjects: 10
Study 16958947 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 12768948 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 25
Study 12768948 — intervention group
Group type: COMPARATOR
Intervention: human insulin 30/70
Number of subjects: 25
Study 11575978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 8 mg twice daily
Number of subjects: 600
Study 11575978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 12 mg twice daily
Number of subjects: 600
Study 11575978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 18 mg twice daily
Number of subjects: 600
Study 11575978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 24 mg twice daily
Number of subjects: 600
Study 11575978 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg subcutaneously twice daily
Number of subjects: 600
Study 9713666 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive method using simulated patients
Number of subjects: 12
Study 9713666 — intervention group
Group type: COMPARATOR
Intervention: Didactic method
Number of subjects: 12
Study 8201222 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (alone or in combination with corticosteroid withdrawal)
Number of subjects: 50
Study 8201222 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (alone)
Number of subjects: 50
Study 8201222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 50
Study 8201222 — intervention group
Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 50
Study 2740834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CH and Triton X‐100
Number of subjects: 10
Study 2740834 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine alone
Number of subjects: 10
Study 2740834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 10
Study 31603351 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare (THCa) system for transmission and online analysis of capillary glucose data
Number of subjects: 161
Study 31603351 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the clinic
Number of subjects: 161
Study 28754483 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg in two 150 mg tablets, twice daily)
Number of subjects: 295
Study 28754483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 28754483 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 295
Study 25816723 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-viewing echoendoscope
Number of subjects: 41
Study 25816723 — intervention group
Group type: COMPARATOR
Intervention: Oblique-viewing echoendoscope
Number of subjects: 41
Study 23707402 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS program (n = 23)
Number of subjects: 52
Study 23707402 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 52
Study 21849726 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite cyclists
Number of subjects: 128
Study 21849726 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary individuals)
Number of subjects: 128
Study 19641893 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital treatment and emergency management of pediatric trauma patients
Number of subjects: 624
Study 19641893 — intervention group
Group type: COMPARATOR
Intervention: Prehospital treatment and emergency management of adult trauma patients
Number of subjects: 624
Study 19641893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric trauma patients
Number of subjects: 624
Study 19641893 — intervention group
Group type: COMPARATOR
Intervention: Adult trauma patients
Number of subjects: 624
Study 17178217 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-fluticasone propionate 500 microg BD/salmeterol 100 microg BD/HFA-tiotropium bromide 18 microg od
Number of subjects: 18
Study 17178217 — intervention group
Group type: COMPARATOR
Intervention: HFA-fluticasone propionate 500 microg BD/salmeterol 100 microg BD matched placebo
Number of subjects: 18
Study 15519629 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 20
Study 15519629 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 15519629 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI facilities
Number of subjects: 20
Study 15519629 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI area
Number of subjects: 20
Study 15519629 — intervention group
Group type: COMPARATOR
Intervention: Non-IMCI area
Number of subjects: 20
Study 11502143 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership caseload midwifery care
Number of subjects: 611
Study 9780093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered intraocular pressure by 30% from baseline
Number of subjects: 140
Study 9780093 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 140
Study 7825247 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cytotoxic drug regimens
Number of subjects: 0
Study 7825247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 7825247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 29420992 — intervention group
Group type: EXPERIMENTAL
Intervention: High acceptability meal (HA) - vanilla custard without acesulfame-K
Number of subjects: 11
Study 29420992 — intervention group
Group type: COMPARATOR
Intervention: Low acceptability meal (LA) - vanilla custard with acesulfame-K
Number of subjects: 11
Study 29420992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals (HA and LA)
Number of subjects: 11
Study 26319101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity variable amplitude spinal manipulation (LVVA-SM)
Number of subjects: 221
Study 26319101 — intervention group
Group type: COMPARATOR
Intervention: Sham control intervention
Number of subjects: 221
Study 26319101 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity low amplitude spinal manipulation (HVLA-SM)
Number of subjects: 221
Study 24462242 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 0
Study 24462242 — intervention group
Group type: COMPARATOR
Intervention: Historical control period
Number of subjects: 0
Study 22585294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck mucosal eversion (BNM‐eversion) during radical retropubic prostatectomy (RRP)
Number of subjects: 211
Study 22585294 — intervention group
Group type: COMPARATOR
Intervention: No bladder neck mucosal eversion (control group) during radical retropubic prostatectomy (RRP)
Number of subjects: 211
Study 21199608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training (BAT)
Number of subjects: 6
Study 21199608 — intervention group
Group type: COMPARATOR
Intervention: Distributed constraint-induced therapy (dCIT)
Number of subjects: 6
Study 18565091 — intervention group
Group type: EXPERIMENTAL
Intervention: Single brief flashes of light
Number of subjects: 12
Study 18565091 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple brief flashes of light
Number of subjects: 12
Study 15784155 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based prevention program
Number of subjects: 0
Study 15784155 — intervention group
Group type: COMPARATOR
Intervention: Routine prevention
Number of subjects: 0
Study 12852472 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal x rays (2 or more x rays)
Number of subjects: 701
Study 12852472 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism in APE gene (ex 5)
Number of subjects: 701
Study 12852472 — intervention group
Group type: EXPERIMENTAL
Intervention: HMLH1 (ex 8)
Number of subjects: 701
Study 10561201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 161
Study 10561201 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 161
Study 10561201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone added to prednisone after 6 weeks
Number of subjects: 161
Study 8902431 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 200 mg
Number of subjects: 6
Study 8902431 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg (racemic mixture)
Number of subjects: 6
Study 1861872 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (mean dose, 201 mg/day)
Number of subjects: 20
Study 1861872 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 20
Study 6961952 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 59
Study 6961952 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 59
Study 6961952 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 31878821 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ADHD
Number of subjects: 116308
Study 31878821 — intervention group
Group type: COMPARATOR
Intervention: Children without ADHD
Number of subjects: 116308
Study 31100237 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 400
Study 31100237 — intervention group
Group type: EXPERIMENTAL
Intervention: No ADT
Number of subjects: 400
Study 31100237 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) in WW group
Number of subjects: 400
Study 27044532 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Number of subjects: 1028
Study 27044532 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II LVAS
Number of subjects: 1028
Study 25198030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a 5 grass pollen mixture
Number of subjects: 78
Study 25198030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22324968 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 30
Study 22324968 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme™
Number of subjects: 30
Study 20032493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (LF)
Number of subjects: 771
Study 20032493 — intervention group
Group type: COMPARATOR
Intervention: High-fat, low-carbohydrate diet (HF)
Number of subjects: 771
Study 20032493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF) for homozygous T-risk allele carriers
Number of subjects: 771
Study 20032493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 771
Study 18997650 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 10
Study 15661598 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenSTAR Program (abstinence-centered sex education program) applied to 210 students in the 1997 cohort
Number of subjects: 1259
Study 15661598 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenSTAR Program (abstinence-centered sex education program) applied to 328 students in the 1998 cohort
Number of subjects: 1259
Study 15661598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in the 1997 cohort
Number of subjects: 1259
Study 15661598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in the 1998 cohort
Number of subjects: 1259
Study 11823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Number of subjects: 9
Study 11823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg) + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Number of subjects: 9
Study 11823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg) + Saline (10 ml 10 min before exercise)
Number of subjects: 9
Study 11823078 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Number of subjects: 9
Study 10087725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 408
Study 10087725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 7677239 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing filter
Number of subjects: 9
Study 7677239 — intervention group
Group type: COMPARATOR
Intervention: No breathing filter
Number of subjects: 9
Study 7677239 — intervention group
Group type: COMPARATOR
Intervention: Two breathing filters connected in parallel
Number of subjects: 9
Study 2188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream (Elimite)
Number of subjects: 94
Study 2188239 — intervention group
Group type: COMPARATOR
Intervention: Crotamiton 10% cream (Eurax)
Number of subjects: 94
Study 6989683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoprolol
Number of subjects: 9
Study 6989683 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol
Number of subjects: 9
Study 31173179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 80
Study 31173179 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 28986203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised inhaled unfractionated heparin (UFH) 150,000 IU BID for 21 days
Number of subjects: 40
Study 28986203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised inhaled unfractionated heparin (UFH) 75,000 IU BID for 21 days
Number of subjects: 40
Study 28986203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26853211 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Oral Health Literacy Project (IOHLP) participants
Number of subjects: 0
Study 26853211 — intervention group
Group type: COMPARATOR
Intervention: National Survey of Adult Oral Health (NSAOH) participants
Number of subjects: 0